Dr. Samarth Kulkarni has served as CRISPR Therapeutics’ Chief Executive Officer since 2017. He has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer and was appointed President and Chief Business Officer before becoming Chief Executive Officer.
Prior to joining CRISPR Therapeutics, Sam was a partner at McKinsey & Company, where he had a leading role in the pharmaceutical and medical products practice. While at McKinsey, he co-led the biotech practice, where he focused on strategy and operations and led initiatives in areas such as personalized medicine and immunotherapy.
Sam also serves on the board of 2 precision oncology companies, Black Diamond Therapeutics and Repare Therapeutics, and on the board of the Emerging Companies Section of the Biotechnology Innovation Organization (BIO). Previously, Sam served as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR Therapeutics and Bayer.
Sam received a PhD in bioengineering and nanotechnology from the University of Washington and a Bachelor of Technology degree from the Indian Institutes of Technology. While at the University of Washington, he conducted research on the delivery of biological drugs and in the field of molecular diagnostics.
Sam has authored several publications in leading scientific and business journals.
